healx


Introduction to Healx and our technologies

AUTM Connect & Collaborate

Dr. Bruce Bloom, Chief Collaboration Officer

28 October, 2021

A few facts about Healx




Mission

Mission-driven company developing novel therapies for the 95% of rare diseases without effective treatments



Growth

High-growth AI tech company founded 2014 in Cambridge, UK. Closed Series A in 2018 and \$56m Series B round in Q4 2019



Tech

Innovative AI and ML models derive novel disease-drug predictions from the world's most comprehensive rare disease knowledge graph

Al-powered, patient-inspired drug discovery



Patient insight is key

- Real world data contributed by patients
- Partnership model
- Rare Treatment
 Accelerator programme



Scalable AI / ML technology

- Outstanding performance metrics
- World class AI data scientists
- Most comprehensive rare disease knowledge graph



Strong drug discovery expertise

- Start with known drugs and nutraceuticals
- Rare disease know-how
- Expertise with a track record of drug discovery

Building clinical pipelines – at scale

Indication	In silico drug dise	covery	Preclinical validation	IND-enab	ling and Clinical planning	Phase 1/2a
Fragile X syndrome						
Pitt Hopkins syndrome						
Autosomal dominant polycystic kidney disease (ADPKD)		1				
Neurofibromatosis type 1 - cutaneous neurofibroma (cNF)						
Neurofibromatosis type 1 - plexiform neurofibroma (pNF)						
Chronic pancreatitis		1	-	1		
Facioscapulohumeral muscular dystrophy (FSHD)			-			
Friedreich's ataxia			-			
Undisclosed disease		1				
Undisclosed disease		1	-•			
COVID-19						
Angelman syndrome						
Undisclosed disease		· · ·				
Autosomal recessive polycystic kidney disease (ARPKD)						
Undisclosed disease		1				
Undisclosed disease		1				
Undisclosed disease		1 				
Undisclosed disease		1				
Rare neurodevelopmental	renal Rare oncology	Rare inflammatory	Rare neuromuscular	Rare respiratory	Rare bone Rare eye	• Rare neurodegenerative

Co-development / in-licensing

Healx looking for re-development assets for rare diseases that are:

- From academic or industry partners
- Drug(s) approved for human use in one or more jurisdictions
- Deprioritized/shelved/discontinued assets that are safe for human use

Healx preferred deal arrangements:

- License preclinically proven assets ready for/close to clinical development
- Option/co-fund assets needing additional pre-clinical development

Keep in touch



Dr Bruce Bloom Chief Collaboration Officer bruce.bloom@healx.io



Dr Mark Youssef Global Head of BD&L mark.youssef@healx.io



Eugenia Wachters VP Operations and Commercial Portfolio Strategy eugenia.wachters@healx.io



Dr Clara Tang Business Manager – Alliance Strategy Manager <u>clara.tang@healx.io</u>